Previous 10 | Next 10 |
2024-03-05 10:30:29 ET Summary Geron Corporation's lead candidate, imetelstat, is awaiting FDA approval for the treatment of transfusion-dependent anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes. The company reported a loss from operations of $19...
2024-02-28 11:45:15 ET Image source: The Motley Fool. Geron (NASDAQ: GERN) Q4 2023 Earnings Call Feb 28, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Geron (GERN) Q4 2023 Earnings Call Transcript
SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...
2024-02-25 08:00:00 ET The last week of February promises a dynamic mix of earnings reports across various sectors. In the technology space, investors are eagerly anticipating updates from Salesforce ( NYSE: CRM ), Snowflake ( NYSE: SNOW ), Zoom Video Communications ( NASD...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2023 financial results and business highlights before the market opens on Wednesday, February 28, 2024 via press release, which will be availabl...
2024-01-29 15:13:38 ET More on Karuna Therapeutics Karuna Therapeutics: Rewiring The Schizophrenia Paradigm - A Novel Leap Beyond Dopamine Karuna Therapeutics, Inc. (KRTX) Q3 2023 Earnings Conference Call Transcript M&A activity expected to pick up in 2024, banke...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat at the B. Riley Securities Virtual Oncology Conference on Thursday, J...
2023-12-26 22:26:33 ET Summary Geron's Imetelstat shows promise for LR-MDS, especially for patients unresponsive to first-line treatments like ESAs, lenalidomide, or HMAs. Geron's financials are strong with a healthy current ratio and sufficient cash runway, but future funding nee...
2023-12-15 10:48:17 ET Penny stocks are the jittery nerves of the stock market – even minor news events can make them swing unpredictably. By definition, penny stocks are shares of companies traded below $5 per share and display extreme percentage changes from relatively insi...
Imetelstat is currently under regulatory review by the FDA and EMA for the treatment of transfusion-dependent anemia in adult patients with lower risk MDS Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced presentations of data from ...
News, Short Squeeze, Breakout and More Instantly...
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday. Shares of Spirit Airlines, Inc. (NYSE:SAVE) fell sharply duri...
2024-05-03 00:30:12 ET Image source: The Motley Fool. Geron (NASDAQ: GERN) Q1 2024 Earnings Call May 02, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Geron (GERN) Q1 2024 Earnings Call Transcript
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...